US Cancer Generics Sector US Cancer Sales Report 2022

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Cancer Generics: A Modest Regimen
1.1 Introduction to Cancer Generics
1.2 Why There Exist is Need for Generic Forms?
1.3 Supremacy of Cancer Generic Drugs
1.3.1 Cost
1.3.2 Quality and Safety
1.3.3 Large Number of Manufacturer
1.3.4 Approved by FDA
1.3.5 Concerns in Cancer Generic Medication

US Generic Drugs Legislature
2.1 Hatch-Waxman Act, 1984
2.2 The Generic Drugs Chronological Disgrace

Trail towards Patenting of Cancer Generic Drugs
3.1 US Generic Pharmaceutical Regulation
3.2 Patenting Wars of Cancer Generics in US

Economic Burden of Prescription Drugs in US
4.1 High Cost of Cancer Drugs
4.2 Healthcare Savings by Virtue of Generics

Cancer Generic Drugs: Still Overpriced in US Market
5.1 Innovation is Meaningless if Nobody can Afford It
5.2 Why US Contends More in Generics?

US Health Insurance Scenario and Cancer
6.1 Provisions for Cancer Drug Coverage
6.2 Private Health Insurance Options
6.3 Government Funded Insurance

Aspects of Branded and Non-Branded Generics
7.1 Debut of Authorized Generics in Market
7.2 Anti-Authorized Generic Legislation

Generics in Oncology World
8.1 Anti-Cancer Targeted Therapy Drugs
8.2 Status of Generics in Monoclonal Antibodies
8.3 Crusade of Small Molecule Inhibitor towards Generics

FDA Approved Anti-Cancer Generics in US
9.1 Taxotere (Generic Docetaxel)
9.2 Imatinib (Generic Glivec)
9.3 Sorafinib ( Generics Nexavar)

US Cancer Generics Market Overview
10.1 US Cancer Generics Market Introduction
10.2 Europe Generics Market Contrary to US
10.3 Asia Generics Market Contrary to US

Cancer Generics Drug Market Dynamics
11.1 Accelerative Parameters
11.1.1 Expiration of Patents
11.1.2 Unaffordability of Cancer Drugs
11.1.3 Cost Containment by Government
11.1.4 Generic Drug User Fee Amendments (2012)
11.1.5 High Cancer Risk and Aging Population of US
11.2 Pitfalls Confronted by Generic Industry

US Cancer Generics Market Future Prospect

Download Report: https://www.kuickresearch.com/report-us-cancer-generics-market-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.